Abstract
COMPARISON BETWEEN HALOPERIDOL AND RISPERIDONE IN DEVELOPMENT OF METABOLIC SYNDROME IN INDIAN PATIENTS

Chaitanya Patel* Praveen Kumar Vodala, Bellanirys Acosta Arias, Abdul Hanan, Francois Antoine Jr. Legagneur, Beenish Sohail Bhutta

ABSTRACT

Introduction: It is well known that anti-psychotics are associated with many side effects. One of the significant adverse drug reactions among these is weight gain and development of metabolic syndrome. In this study, we compared the most widely used drugs Haloperidol and Risperidone for development of metabolic syndrome in treatment naïve patients with one episode of Schizophrenia. Methods: We took a total of 45 patients who were diagnosed to have Schizophrenia. All these patients never took any anti-psychotic in their live, nor did they take any other medicine for CNS/Psychiatry disorder. Among these 45 patients, 16 patients were put on Haloperidol and 29 patients were prescribed Risperidone. Patients with endocrine disturbances, any systemic disorders, etc. were removed from the study. The baseline characteristics of all the patients were properly studied and recorded. The characteristics were recorded again after 6 months and comparison was done by statistical methods. Results: PANSS score showed a decrease in both groups, systolic blood pressure showed an increase with Haloperidol and an initial decrease with risperidone while diastolic blood pressure increased with haloperidol. Weight gain, increase in waist circumference, rise in triglyceride levels and fall in HDL cholesterol were equally observed in both groups. Increase in plasma glucose was seen more with risperidone (93.1%). 18.86% (n = 10) developed metabolic syndrome at the end of 6months with no difference in emergence between both groups. Conclusion: Risperidone is considered equivalent to Haloperidol in efficacy but it is associated with increase in the components of metabolic syndrome.

Keywords: It is well known Risperidone metabolic syndrome.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tanima Debnath Sarkar

Download Article : Click here

News & Updation

  • EJBPS: OCTOBER ISSUE PUBLISHED

    OCTOBER 2021 Issue has been successfully launched on 1 October 2021

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT